Evidence map›Paper›PMID 23593203›Full record

ArticlePloS one2013

The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.

Heevy Al-Chaqmaqchi, Behnam Sadeghi, Manuchehr Abedi-Valugerdi, Sulaiman Al-Hashmi, Mona Fares, Raoul Kuiper, Joachim Lundahl, Moustapha Hassan, Ali Moshfegh

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03480360 (Haploidentical Allogeneic Peripheral Blood Transplantation), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03480360 phase3completednot on this mapstarted 2018, after this paper: background citation

Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression

TypeinterventionalSponsorDartmouth-Hitchcock Medical CenterRan2018 to 2025Enrolled21ConditionsAcute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, MyelodysplasiaArmsCyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Accumulation of T-cell-suppressive PD-L1Journal for immunotherapy of cancer · 2023
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Heevy Al-ChaqmaqchiDepartment of Laboratory Medicine, Division of Clinical Research Center, Experimental Cancer Medicine, Karolinska Institutet, Stockholm, Sweden.
Behnam Sadeghi
Manuchehr Abedi-Valugerdi
Sulaiman Al-Hashmi
Mona Fares
Raoul Kuiper
Joachim Lundahl
Moustapha Hassan
Ali Moshfegh
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death ligand-1 (PD-L1/CD274) is an immunomodulatory molecule involved in cancer and complications of bone marrow transplantation, such as graft rejection and graft-versus-host disease. The present study was designed to assess the dynamic expression of this molecule after hematopoietic stem cell transplantation in relation to acute graft-versus-host disease. Female BALB/c mice were conditioned with busulfan and cyclophosphamide and transplanted with either syngeneic or allogeneic (male C57BL/6 mice) bone marrow and splenic cells. The expression of PD-L1 was evaluated at different time points employing qPCR, western blot and immunohistochemistry. Allogeneic- but not syngeneic-transplanted animals exhibited a marked up-regulation of PD-L1 expression in the muscle and kidney, but not the liver, at days 5 and 7 post transplantation. In mice transplanted with allogeneic bone marrow cells, the enhanced expression of PD-L1 was associated with high serum levels of IFNγ and TNFα at corresponding intervals. Our findings demonstrate that PD-L1 is differently induced and expressed after allogeneic transplantation than it is after syngeneic transplantation, and that it is in favor of target rather than non-target organs at the early stages of acute graft-versus-host disease. This is the first study to correlate the dynamics of PD-L1 at the gene-, protein- and activity levels with the early development of acute graft-versus-host disease. Our results suggest that the higher expression of PD-L1 in the muscle and kidney (non-target tissues) plays a protective role in skeletal muscle during acute graft-versus-host disease.

Indexed as

Gene Expression RegulationAnimalsB7-H1 AntigenBone Marrow TransplantationFemaleGene Expression ProfilingGraft vs Host DiseaseInterferon-gammaKidneyLiverMaleMiceMice, Inbred BALB CMice, Inbred C57BLMusclesRNA, MessengerB7-H1 AntigenInterferon-gammaRNA, MessengerTumor Necrosis Factor-alpha

Identifiers

PMID23593203
PMCPMC3617218
OpenAlexW2075687542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.